Retatrutide has emerged as a new medication in the fight against obesity. This novel drug, classified as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in clinical trials. By stimulating these https://barbarakrnu962276.bloggin-ads.com/59331925/tirzepatide-a-promising-new-treatment-for-obesity